Therapeutics Bridge Labs (TxBL), launched by MSK in 2025 and embedded within OEC, represents a unique strategic asset among New York City academic research institutions.

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Research at MSK Our research impact Research topics Core facilities & resources ...

How are new targeted therapies for specific genetic mutations improving lung cancer treatment? We are getting new targeted therapies approved every year for genes that were long thought to be ...

Research at MSK Our research impact Research topics Core facilities & resources ...

The Exercise Oncology Service brings together scientists and physiologists to study the effect of physical activity on cancer treatment and prognosis. For years, people with cancer and their doctors ...

MSK gastrointestinal medical oncologist Eileen O'Reilly, MD (left), led a very promising early phase clinical trial of the targeted RAS therapy daraxonrasib for people facing pancreatic cancer.

For people living with advanced triple-negative breast cancer (TNBC), a newly approved treatment may offer more time and a better quality of life. TNBC makes up about 10% to 20% of all breast cancers, ...

MSK gastrointestinal medical oncologist Dr. Wungki Park led the early phase clinical trial of daraxonrasib for people with metastatic pancreatic cancer that had stopped responding to chemotherapy.

Stomach (gastric) cancer is the third leading cause of cancer deaths in the world today. About 10% of these cancers are due to a genetic mutation inherited from a parent. One specific mutation, called ...

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.